Tiziana Life Sciences (TLSA) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Tiziana Life Sciences has received FDA Fast Track designation for its intranasal foralumab, aiming to treat Secondary Progressive Multiple Sclerosis (SPMS) and potentially other neurodegenerative diseases. The designation will expedite the review process and enhance the company’s interaction with the FDA, highlighting foralumab’s potential to meet an unmet medical need. Additionally, Tiziana is addressing Nasdaq compliance issues to prevent the delisting of its shares.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.